Project description:We employed Single cell RNA-seq to identify the transcriptome of cisplatin sensitive, resistant and drug-holiday cells from patient-derived OSCC cells isolated from primary and metastatic sites.
Project description:Chemoresistance frequently leads to therapeutic failure in oral squamous cell carcinoma (OSCC). While miRNA have been widely reported having global regulatory roles in cancer biological properties, yet their localiztion alteration under cisplatin treatment has not been clarified. In this study, to identify the sublocalization characteristics of miRNAs induced by chemotherapy, especially the specific mitochondrial localization of miRNA, we profile the expression of miRNAs in cisplatin-resistant and parental TSCC cells using miRNA microarrays.
Project description:We report the application of methyl-binding protein sequencing (MBD-seq) to global identify aberrant methylation between cisplatin sensitive and resistant ovarian cancer cell lines Detection of aberrant methylation states between cisplatin sensitive and resistant cell lines
Project description:Cisplatin is a commonly used platinum-based chemotherapeutic agent for oral squamous cell carcinoma (OSCC). However, cisplatin efficacy is limited by drug toxicity and the resistance capabilities of cancer cells. Reduced efficacy of anticancer therapy has been recently attributed to the presence of therapy-insensitive subpopulations in heterogeneous tumours, known as cancer stem-like cells (CSCs). CSCs comprise a tumour-forming subpopulation of cells that exhibit stem cell-like features, including the abilities to self-renew and turn into progenitor and differentiated cancer cell lineages, and enhanced therapeutic resistance capabilities, thus driving the continual growth and survival of tumours. Overall, this work was conducted to provide the transcriptomes of the OSCC cell lines with differing responses to cisplatin using a microarray analysis. The data may be analyzed alongside other similar datasets to explore the underlying cisplatin resistance mechanisms in OSCC.
Project description:Cisplatin-resistant gastric cancer (GC) occurs in patients with GC treated with cisplatin-based chemotherapy, which results in disease progression and early recurrence during the treatment. To understand the initiation and developmental mechanism underlying cisplatin-resistant GC, we developed cisplatin resistant SGC7901 cells (SGC7901/DDP) from the parental cells (SGC7901/S) by continuous exposure to increasing concentrations of cisplatin and subjected these two cell lines to RNA sequencing analysis.
Project description:Oral squamous cell carcinoma (OSCC) represents a major malignancy in the oral and maxillofacial region. The primary therapeutic agents, 5-fluorouracil (5FU) and oxaliplatin (OXA), often encounter the challenge of chemoresistance, leading to treatment failure. The WNT/β-catenin signaling pathway, closely tied with chemoresistance, offers a promising therapeutic avenue. This study delves into this potential connection. 5FU-resistant and OXA-resistant cell lines were established by gradually elevating the drug concentration in the culture medium. Differential gene expressions between parental and resistant cells were analyzed by RNA sequencing analysis, which was then substantiated via RT-qPCR and western blot. The influence of the WNT signaling on OSCC drug resistance was ascertained through WNT3 knockdown or overexpression. The WNT inhibitor, MSAB, was probed for its capacity to boost the efficacy of 5FU or OXA. Through transcriptome sequencing, successfully derived 5FU-resistant and OXA-resistant cell lines revealed a conspicuous activation of the WNT/β-catenin signaling pathway in the drug-resistant cells. WNT3 was identified as a pivotal factor contributing to chemoresistance in OSCC. Counteracting β-catenin notably augmented the therapeutic potency of 5FU and OXA. Our study underscored the activation of the WNT/β-catenin signaling pathway in resistant OSCC cell lines. By modulating WNT signaling activity, drug resistance in OSCC cells may be effectively circumvented.
Project description:chemoresistance frequently leads to therapeutic failure in oral squamous cell carcinoma (OSCC). Recently, studies have reported that lncRNAs play active roles in regulation biological properties of cancer and may regulate the expression of miRNA. We also found that miRNAs could regulate cisplatin sensitivity in TSCC previously. In this study, to explore the potential targets of lncRNAs in response to cisplatin, we performed microarray to detect miRNAs both in control and NR_034085–silenced CAL-27 and SCC-9 cells under cisplatin treatment.
Project description:Differential expression of miRNAs between parental and cisplatin-resistant PDAC cells was analyzed to elucidate the role of miRNAs in the acquired resistance of pancreatic cancer cells to cisplatin. Cisplatin-resistant BxPC3-R cells were developed from the parental BxPC3 cell line by culturing them in medium with step-wise increasing concentration of cisplatin.
